Eli Lilly is rolling out its Open Innovation Drug Discovery platform to cast a wide net for finding innovative molecules from external investigators in the company's core disease focus areas. The pharma has also joined a public-private partnership being led by the Structural Genomics Consortium to identify IP-free molecules against epigenetic targets.